

PAGE et al -- Serial No.: 09/495,861

vector encoding a heavy chain of said therapeutically effective antibody;

(ii) introducing said vectors of step (i) into a Chinese hamster ovary (CHO) cell;

(iii) culturing said CHO cell in a culture medium so that said light and heavy chains are produced and a CHO glycosylated therapeutically effective antibody is thereby produced;

(iv) recovering said therapeutically effective antibody of step (iii);

(v) administering the antibody of step (iv) in a therapeutically effective amount to said human.

49. The method of claim 48 wherein the antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.

50. The method of claim 48 wherein the human is afflicted with a T-cell disorder.

51. The method of claim 50 wherein the T-cell disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.

PAGE et al -- Serial No.: 09/495,861

52. The method of claim 48 wherein the human is afflicted with an autoimmune disease.

53. The method of claim 52 wherein the autoimmune disease is multiple sclerosis, graft vs host disease, psoriasis, Juvenile onset diabetes, Sjogrens disease, thyroid disease, myasthenia gravis, transplant rejection or asthma.

54. The method of claim 48 wherein the human is afflicted with cancer.

55. The method of claim 54 wherein the cancer is non-Hodgkins lymphoma or multiple myeloma.

56. The method of claim 48 wherein the human is afflicted with an infectious disease.

57. The method of claim 56 wherein the infectious disease is HIV or herpes.

58. A method of treating a human in clinical need thereof which method comprises the steps of:

Sub  
D3

PAGE et al -- Serial No.: 09/495,861.

(i) transforming a Chinese hamster ovary (CHO) cell with a recombinant expression vector such that said cell can express an antibody;

(ii) culturing said CHO cell in serum-free medium so that a CHO glycosylated therapeutically effective antibody is thereby produced;

*Sub 3*  
*D*  
*cont*  
(iii) recovering said therapeutically effective antibody of step (ii);

(iv) administering the antibody of step (iii) in a therapeutically effective amount to said human.

59. The method of claim 58 wherein the antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.

60. The method of claim 58 wherein the human is afflicted with a T-cell disorder.

*Sub 4*  
61. method of claim 60 wherein the T-cell disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.

62. The method of claim 58 wherein the human is afflicted with an autoimmune disease.

63. The method of claim 62 wherein the autoimmune disease is multiple sclerosis, graft vs host disease, psoriasis, Juvenile onset diabetes, Sjogrens disease, thyroid disease, myasthenia gravis, transplant rejection or asthma.

64. The method of claim 58 wherein the human is afflicted with cancer.

65. The method of claim 64 wherein the cancer is non-Hodgkins lymphoma or multiple myeloma.

66. The method of claim 58 wherein the human is afflicted with an infectious disease.

67. The method of claim 66 wherein the infectious disease is HIV or herpes.

68. The method of claim 58 wherein the cell is cultured in said serum-free medium for greater than two months.

PAGE et al -- Serial No.: 09/495,861

69. The method of claim 68 wherein the cell is cultured in said serum free medium for greater than five months.

70. The method of claim 58 wherein the culture undergoes multiple passage.

71. The method of claim 58 wherein the serum free medium comprises water, an osmolarity regulator, a buffer, an energy source, L-glutamine and at least one additional amino acid, an inorganic iron source and a recombinant growth factor wherein each component of said medium is obtained from a source other than directly from an animal source.

72. The medium of claim 58 wherein the medium is devoid of bovine serum albumin, pure human transferrin and soyabean lecithin.

73. The method of claim 58 wherein the growth factor is recombinant insulin.